4/17
04:05 pm
oric
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Low
Report
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
4/16
10:00 am
oric
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
4/15
10:58 pm
oric
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
4/14
05:01 pm
oric
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
4/6
08:06 am
oric
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Low
Report
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
4/6
05:32 am
oric
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data [Yahoo! Finance]
Low
Report
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data [Yahoo! Finance]
4/3
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/2
08:01 am
oric
Oric Pharmaceuticals (ORIC) had its "buy" rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
High
Report
Oric Pharmaceuticals (ORIC) had its "buy" rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
4/2
04:38 am
oric
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 [Yahoo! Finance]
High
Report
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 [Yahoo! Finance]
4/1
01:17 pm
oric
ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation [Seeking Alpha]
High
Report
ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation [Seeking Alpha]
4/1
09:01 am
oric
Oric Pharmaceuticals (ORIC) had its price target lowered by Wedbush from $20.00 to $17.00. They now have an "outperform" rating on the stock.
High
Report
Oric Pharmaceuticals (ORIC) had its price target lowered by Wedbush from $20.00 to $17.00. They now have an "outperform" rating on the stock.
4/1
04:37 am
oric
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript [Seeking Alpha]
High
Report
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript [Seeking Alpha]
3/31
07:35 pm
oric
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial [Yahoo! Finance]
High
Report
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial [Yahoo! Finance]
3/31
04:05 pm
oric
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
High
Report
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
3/27
08:59 am
oric
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC [Yahoo! Finance]
Low
Report
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC [Yahoo! Finance]
3/27
08:30 am
oric
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
Low
Report
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
3/17
05:01 pm
oric
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
High
Report
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
3/13
05:34 am
oric
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns [Yahoo! Finance]
Medium
Report
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns [Yahoo! Finance]
3/12
10:33 pm
oric
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Medium
Report
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility [Yahoo! Finance]
3/9
04:05 pm
oric
Oric Pharmaceuticals (ORIC) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Medium
Report
Oric Pharmaceuticals (ORIC) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
3/6
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
High
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/25
11:03 am
oric
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright [Yahoo! Finance]
Low
Report
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright [Yahoo! Finance]
2/24
10:58 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at HC Wainwright from $23.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at HC Wainwright from $23.00 to $25.00. They now have a "buy" rating on the stock.
2/24
08:54 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
2/24
07:01 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at Citigroup Inc..